See more : LG Chem, Ltd. (051910.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Bullfrog AI Holdings, Inc. Common Stock (BFRG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bullfrog AI Holdings, Inc. Common Stock, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- DCM Corp. (024090.KS) Income Statement Analysis – Financial Results
- IG Acquisition Corp. (IGACW) Income Statement Analysis – Financial Results
- PRTS CAM Pte. Ltd. (PRTOF) Income Statement Analysis – Financial Results
- Venus Pipes and Tubes Limited (VENUSPIPES.BO) Income Statement Analysis – Financial Results
- Panafic Industrials Limited (PANAFIC.BO) Income Statement Analysis – Financial Results
Bullfrog AI Holdings, Inc. Common Stock (BFRG)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.bullfrogai.com
About Bullfrog AI Holdings, Inc. Common Stock
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 65.00K | 10.00K | 0.00 | 0.00 |
Cost of Revenue | 5.20K | 800.00 | 0.00 | 0.00 |
Gross Profit | 59.80K | 9.20K | 0.00 | 0.00 |
Gross Profit Ratio | 92.00% | 92.00% | 0.00% | 0.00% |
Research & Development | 1.43M | 609.27K | 0.00 | 0.00 |
General & Administrative | 3.99M | 1.86M | 555.36K | 347.19K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 3.99M | 1.86M | 555.36K | 347.19K |
Other Expenses | 0.00 | 459.00 | 0.00 | 0.00 |
Operating Expenses | 5.43M | 2.47M | 555.36K | 347.19K |
Cost & Expenses | 5.43M | 2.47M | 555.36K | 347.19K |
Interest Income | 183.70K | 459.00 | 0.00 | 0.00 |
Interest Expense | 79.09K | 347.15K | 40.40K | 11.77K |
Depreciation & Amortization | 1.73K | 1.05K | 236.56K | 206.30K |
EBITDA | -5.28M | -2.45M | -555.36K | -347.19K |
EBITDA Ratio | -8,115.47% | -24,542.97% | 0.00% | 0.00% |
Operating Income | -5.37M | -2.46M | -555.36K | -347.19K |
Operating Income Ratio | -8,257.73% | -24,558.01% | 0.00% | 0.00% |
Total Other Income/Expenses | 11.66K | -346.69K | -30.48K | 5.50K |
Income Before Tax | -5.36M | -2.80M | -585.84K | -341.69K |
Income Before Tax Ratio | -8,239.80% | -28,024.87% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 347.60K | -196.16K | -194.53K |
Net Income | -5.36M | -2.80M | -585.84K | -341.69K |
Net Income Ratio | -8,239.80% | -28,024.87% | 0.00% | 0.00% |
EPS | -0.89 | -0.46 | -0.10 | -0.06 |
EPS Diluted | -0.89 | -0.46 | -0.10 | -0.06 |
Weighted Avg Shares Out | 6.05M | 6.09M | 5.65M | 5.65M |
Weighted Avg Shares Out (Dil) | 6.05M | 6.09M | 5.65M | 5.65M |
BullFrog AI's VP Artificial Intelligence to Present at Google's Cancer AI Symposium
WallachBeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
Bullfrog AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
WallachBeth Capital Announce Pricing of Bullfrog AI's Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114
Top 4 Health Care Stocks That May Keep You Up At Night
BullFrog AI to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets
Source: https://incomestatements.info
Category: Stock Reports